{"id":"W4386102508","doi":"10.1097/01.hs9.0000975836.58931.97","title":"PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Obinutuzumab; Medicine; Ibrutinib; Lenalidomide; Rituximab; Internal medicine; Oncology; Follicular lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukemia; Salvage therapy; Phases of clinical research; Idelalisib; Lymphoma; Clinical trial; Chemotherapy; Leukemia; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009087404,0.001130601,0.001678748,0.0003445472,0.0003858987,0.001499029,0.0009130494,0.001154136,0.00729622],"category_scores_gemma":[0.0005681601,0.0003629568,0.001345146,0.0003198586,0.0006491622,0.0007222084,0.0003904918,0.003423919,0.001506882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009354171,"about_ca_system_score_gemma":0.001423281,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001250774,"about_ca_topic_score_gemma":0.0049818,"domain_scores_codex":[0.9997746,0.00009887092,0.000007951304,0.000033184,0.00002716517,0.00005818073],"domain_scores_gemma":[0.999738,0.00003882233,0.00004270428,0.00001198198,0.00001432869,0.0001542192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7171771,0.02090114,0.002588659,0.002711412,0.002127473,0.0003272354,0.000334395,0.002740693,0.02196296,0.001118726,0.02327518,0.2047351],"study_design_scores_gemma":[0.8754925,0.1050611,0.006436658,0.000161024,0.0005470238,0.0003111005,0.00006901122,0.001329341,0.001432039,0.0005386917,0.008575817,0.00004574624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9549541,0.0215326,0.0005995583,0.003257543,0.0008741294,0.002475213,0.003342821,0.0005602511,0.01240374],"genre_scores_gemma":[0.9668854,0.009948394,0.001638825,0.004145159,0.0005241271,0.001945178,0.00429415,0.0000798285,0.01053895],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00729622,"threshold_uncertainty_score":0.02440834,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03128032831111953,"score_gpt":0.3233636286600862,"score_spread":0.2920833003489667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}